drugset / Trial / NCT00842244

Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

NCT00842244

Phase 1 Completed 22 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.

Timeline

Start
2009-04
Primary completion
2009-12
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Background Cisplatin Other / unclassified 80 mg/m2 Intravenous

Indications